Orexo AB has announced a multi-year agreement with UnitedHealth Group and OptumRx providing preferred coverage and reimbursement of Zubsolv.

Zubsolv is a sublingual tablet formulation for maintenance treatment of opioid dependence. Under the agreement, the product will be given preferred, Tier 2 brand status on UnitedHealth Group commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid dependence through June 30, 2014. Beginning on July 1, 2014 Zubsolv will become the only buprenorphine/naloxone combination product on all of UnitedHealth’s closed and highly managed health plan formularies, inclusive of all brand and generic formulations.

“Orexo is dedicated to broadening the market access position for Zubsolv and this agreement with UnitedHealth Group and OptumRx is an important step in that direction. It is a major achievement and endorsement as health insurers with a firm control over their formularies recognize Zubsolv as the preferred buprenorphine/naloxone formulary product for the maintenance treatment of opioid dependence” said Nikolaj Sorensen, CEO and President of Orexo, in a press release.

Source: Orexo